Synthesis of a fluorescent derivate of Argyrin A

Slides:

Advertisements

Similar presentations

Calculus and Cancer Drug Development Studies Stephan Gysin, PhD UCSF Helen Diller Family Comprehensive Cancer Center.

Advertisements

CONTEXT SPECIFIC ROLE OF DEUBIQUITYLASE ENZYME, USP9X, IN HEAD AND NECK CANCER Devathri Nanayakkara Eskitis Institute for Drug Discovery Griffith University.

IMIQUIMOD, AN IMMUNE-RESPONSE MODIFIER, IN THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER Douglas Scherr, M.D. Department of Urology New York.

The Use of a Vesicular Delivery System in the Enhancement of Cisplatin Bioavailability Manal M. Alsaadi, Katharine C. Carter and Alexander B. Mullen Strathclyde.

The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.

Kui Wang May 6th, 2017.

Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.

Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.

Cell Physiol Biochem 2016;38: DOI: /

Introduction Conclusions

University of New South Wales, Sydney, Australia

Genetics and pathology of pancreatic cancer

A new therapeutic antibody masks ErbB2 to its partners

Table 1. Scientific findings of previously published work on Graviola

Drug product performance and generic drug product development

Atsushi Masamune, Takashi Watanabe, Kazuhiro Kikuta, Tooru Shimosegawa

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

Jens T. Siveke, Roland M. Schmid Cancer Cell

A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor.

Volume 114, Issue 2, Pages (February 1998)

Volume 14, Issue 1, Pages (July 2008)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Finding and Killing the CRABs of Pancreatic Cancer

Desmoplasia of Pancreatic Ductal Adenocarcinoma

Antitumor activity of BAY in patient-derived tumor models.

Moorthy P. Ponnusamy, Surinder K. Batra Gastroenterology

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

A new therapeutic antibody masks ErbB2 to its partners

David A. Tuveson, John P. Neoptolemos Cell

Expression of THBS2 in human PanIN tissue and PDAC tumor tissue

Mitochondrial cardiolipin plays a key role in macrophage inflammasome activation in response to apoptotic mitochondria. Mitochondrial cardiolipin plays.

Antitumor effects of FF and gemcitabine on two pancreatic PDX models.

A new mouse model of pancreatic cancer: PTEN gets its Akt together

Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis Shinji Tanaka, Jack R. Wands, Shigeki.

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

Induction of apoptosis by NMT siRNAs.

Volume 151, Issue 2, Pages (August 2016)

A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

In vitro invasion assays were done in the Chemicon invasion chamber containing extracellular matrix. In vitro invasion assays were done in the Chemicon.

Effects of WDL on in vitro invasion and soft agar colony formation by LNCaP cells. Effects of WDL on in vitro invasion and soft agar colony formation by.

Overexpression of miR-335, but not miR-29a, reduces in vitro carcinogenesis. Overexpression of miR-335, but not miR-29a, reduces in vitro carcinogenesis.

IL-13Rα2 promotes cell survival and proliferation.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

Oncoprotein synthesis and mechanism of action of omacetaxine mepesuccinate. Oncoprotein synthesis and mechanism of action of omacetaxine mepesuccinate.

Antitumor effects of celastrol in vitro and in vivo.

Microarray analysis of global gene expression profiles of PC-3 and derivative cell lines. Microarray analysis of global gene expression profiles of PC-3.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

Combination of miR-520d-3p and EphA2 siRNA treatment shows enhanced EphA2 inhibition and antitumor efficiency in vitro. Combination of miR-520d-3p and.

Activation of membrane-associated Akt is associated with loss of apoptosis in TgAPT121;Pten+/− prostates. Activation of membrane-associated Akt is associated.

miR-100 suppresses bladder cancer cell growth in vitro and in vivo.

Reduced klotho expression in pancreatic cancer.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

FBXL19-AS1 knockdown inhibits proliferation, migration and invasion, and reduces the expression levels of angiogenesis related proteins in lung cancer.

Effects of ASGR2 knockdown on the phenotypes of MKN1 cells.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

T cells with a ROR1-specific CAR eliminate tumor cells in vivo only with a modified long spacer. T cells with a ROR1-specific CAR eliminate tumor cells.

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Cells expressing mutant NADK-I90F exhibit low ROS and elevated NADP and NADPH levels. Cells expressing mutant NADK-I90F exhibit low ROS and elevated NADP.

Loss of NQO1 expression inhibits invasion of NSCLC

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Giulia Tarantola, Humanitas University

Presentation transcript:

Synthesis of a fluorescent derivate of Argyrin A A project in collaboration with professor Markus Kalesse, Institut für Organische Chemie, Leibniz Universität Hannover Argyrin A is a cyclical peptide derivated from the myxobacterium Archangium gephyra. Recent studies have demonstrated that Argyrin A has antitumoral activities, in fact it has an important role in the inhibition of 20S proteasome in a new systemic treatment for PDAC (Pancreatic ductal adenocarcinoma). These studies in vitro and in vivo show that Argyrn A inhibits cell proliferation, migration, invasion and colony formation by partial induction of apoptosis. The aim of the project is to synthetize a fluorescent derivate of Argiryn A for studing its mechanism in the cell and allowing a better optimization in the future drug development and an improvement of his pharmacokinetic properties. Argyrin A Cancer Letters 399 (2017) 20e28 W. Wu et al. / Tetrahedron Letters 52 (2011) 2488–2491